Case report: lanreotide in the management of hypercalcemia of malignancy.
The management of hypercalcemia of malignancy (HCM) is difficult if the underlying neoplasm cannot be treated successfully. The overexpression of parathyroid hormone-related protein (PTHrP) by various neoplasms is a common mechanism of HCM and usually is a premorbid event. Current pharmacologic measures to control HCM are directed more toward inhibiting the action rather than inhibiting the secretion of PTHrP. The somatostatin congeners are a novel class of drugs that can inhibit some excessive hormonal states. In this report, the authors summarize an observation made using lanreotide, an investigational somatostatin congener, in treating a patient with a neuroendocrine neoplasm. Lanreotide administration resulted in normalizing the serum calcium levels while decreasing plasma PTHrP concentrations. The chronic administration of lanreotide produced a stable radiographic response and controlled the HCM without adverse side effects. The somatostatin congeners potentially offer another therapeutic modality in managing HCM.
Anthony
L B
LB
Department of Medicine, Vanderbilt University, Nashville, TN 37232, USA.
May
M E
ME
Oates
J A
JA
D000368:Aged; D002118:Calcium / Q000097:blood; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology; D018358:Neuroendocrine Tumors / Q000150:complications* / Q000378:metabolism; D010190:Pancreatic Neoplasms / Q000150:complications* / Q000378:metabolism; D044162:Parathyroid Hormone-Related Protein; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000627:therapeutic use*; D014176:Protein Biosynthesis; D011506:Proteins / Q000378:metabolism; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
C470121:PTHLH protein, human; D044162:Parathyroid Hormone-Related Protein; D010456:Peptides, Cyclic; D011506:Proteins; C060347:lanreotide; D013004:Somatostatin; D002118:Calcium